- PR Newswire•19 days agoCytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas
LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has agreed to a Type B pre-NDA meeting at which the company will seek input on its planned New Drug Application (NDA) for aldoxorubicin as a new second-line treatment for patients with soft tissue sarcomas (STS). Assuming a positive outcome from this pre-NDA meeting, CytRx expects to submit an NDA for aldoxorubicin to the FDA in the last quarter of 2017, and, subject to FDA approval, bring aldoxorubicin to market next year.
- Zacks•24 days ago
Options traders are pricing in a big move for CytRx Corp (CYTR) shares as it has huge implied volatility
- PR Newswire•last month
LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation (CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel Levitt, M.D., Ph.D., the Company's current Executive Vice President and Chief Medical Officer, to the newly created role of Chief Operating Officer. Going forward, Dr. Levitt will continue to serve as CytRx's Chief Medical Officer, a role he has held in since joining CytRx in 2009. "Dan has long been a valuable member of the senior leadership team and his appointment as Chief Operating Officer and Chief Medical Officer only strengthens our ability to successfully implement our strategic goals," said Steven A. Kriegsman, CytRx's Chairman and Chief Executive Officer.
CYTR : Summary for CytRx Corporation - Yahoo Finance
CytRx Corporation (CYTR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||0.41 - 0.44|
|52 Week Range||0.36 - 3.66|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.47|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|